LINCOLN — LINCOLN PHARMACEUTICALS Balance Sheet
0.000.00%
- IN₹12.31bn
- IN₹9.94bn
- IN₹6.71bn
Annual balance sheet for LINCOLN PHARMACEUTICALS, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | 2026 March 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 1,153 | 1,138 | 1,524 | 1,964 | 2,420 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 1,634 | 1,708 | 2,160 | 2,236 | 2,423 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 3,528 | 3,672 | 4,467 | 4,999 | 5,831 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 1,476 | 1,569 | 1,825 | 1,860 | 1,953 |
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 5,344 | 5,874 | 7,003 | 7,970 | 8,904 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 905 | 723 | 923 | 1,062 | 1,110 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Funded Status | |||||
| Total Liabilities | 1,015 | 849 | 1,075 | 1,253 | 1,328 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 4,329 | 5,025 | 5,928 | 6,717 | 7,576 |
| Total Liabilities & Shareholders' Equity | 5,344 | 5,874 | 7,003 | 7,970 | 8,904 |
| Total Common Shares Outstanding |